reason report
posit setup new product revenu allow
hit guidanc
bottom line unlik pressur due
new product approv delay base busi eros like
setup wait major approv
manag well way execut new product
launch drive sale well
resolv manufactur issu morgantown believ
new product sale achiev driven product
wixela gener advair abl reach
even gener penetr meaning
improv current level fulphila appear track
base initi symphoni volum data
coheru recent pre-announc udenyca remain
come new product launch us eu row
detail note refer figur addit eros
oral solid busi come better prior
assumpt overal rais revenu
greater confid manag hit high-singl
digit y/i growth rate segment continu believ
diversifi portfolio underappreci current stock
stock continu trade discount peer execut
guidanc visibl strateg review
drive multipl expans current trade ev/
ebitda one turn gx peer despit
ebitda come higher multipl brand consum segment
warrant higher multipl rang believ
execut guidanc go long way rebuild
investor confid along announc outcom
strateg review like later year drive momentum stock
despit plateau gener advair disku uptak believ
estim achiev base
convers medacorp payer kol believ gsk up
rebat effort stop bleed eros brand
kol indic plan gener current
cheaper brand howev kol believ current
util pattern unlik hold januari
decid lower price captur addit market share
less like gsk follow suit potenti addit
gener competit base experi gener
copaxon believ lower price captur much
market new wixela revenu
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
consensu even assum price discount
subsequ increas wixela share later year still arriv
revenu estim believ sale estim
earli volum trend posit fulphila biosimilar neulasta
coheru pre-announc udenyca suggest adopt
may even swift first two month biosimilar
captur market fulphila captur line
estim howev coheru recent pre-announc
udenyca suggest biosimilar uptak may even
estim chang market share assumpt
remov risk adjust fulphila sale
greater convict adequ meet demand
revis estim consensu believ
higher estim unreason assum share
februari biosimilar share alreadi reach
new product launch revenu north america
line manag guidanc global
estim asid contribut wixela
contribut fulphila analysi iqvia data
suggest contribut newli launch product
specif broken model also includ
launch like yupelri gx cubicin zytiga new
launch gx restasi lyrica biosimilar herceptin
also includ undisclos product believ
reason given histor iqvia data suggest launch
product year
eros oral solid busi appear moder
latest trend suggest y/i impact prior
estim previous publish analysi
triangul iqvia data trend oral solid busi
estim y/i impact three month addit data
eros trend come better prior expect
deriv estim y/i impact morgantown
chang model rais revenu
y/i growth na segment line
manag guidanc high-singl digit vs prior estim
revenu consensu
also increas oper expens slightli front-load
base manag recent commentari quarterli
cadenc earn overal ep increas
slightli consensu ebitda
essenti unchang pt remain
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair opportun may smaller estim commerci uptak
biosimilar may take longer anticip growth ou market may slower
expect market penetr gener copaxon may improv biosimilar neulasta ramp
may slower estim remedi morgantown facil may take longer
allevi reach lower capac current estim
posit setup hit guidanc
stock pressur due overhang new product approv mainli
advair eros base busi morgantown result full-year top-
bottom-lin perform come initi expect manag guidanc
februari top line line prior street estim believ question
achiev revenu analysi earli data trend suggest
well posit reach new product revenu estim base
bottom-up analysi key new product sale driver
iqvia trend suggest eros base busi particularli morgantown
come less sever initi estim
previous found difficult reach manag high single-digit y/i guidanc na
segment greater convict manag abl hit guidanc
manag estim new product revenu appear achiev
unlik continu delay approv wixela uncertainti readi
fulphila slow uptak gx copaxon put pressur new product contribut
believ new product revenu contribut certain note provid
detail three key piec segment
gener advair penetr plateau appear
achiev extrem fast initi uptak subsequ stagnat
past four week believ reason behind larg similar
gx copaxon small price gap brand gener fact remain
abl maintain market share far furthermor progress
year believ aggress price reach market
share level indic typic gener penetr rate estim
sale even doesnt pick share remaind
forecast suggest sale target still achiev
earli sign fulphila posit given earli symphoni trend coheru pre-
announc udenyca track sale last week coheru
pre-announc biosimilar neulasta product sale
significantli higher consensu even assum estim base
januari februari symphoni data higher sale total along manag
recent commentari make us confid see meet
demand get fulphila remov prior risk-adjust yield
estim
contribut newli launch product us appear align
manag guidanc estim analysi iqvia data
contribut newli launch product suggest come
bucket product current specif broken model
new product launch revenu product includ yupelri
launch specif model like gx cubicin new launch specif
model includ gx restasi lyrica biosimilar herceptin bucket also
consist estim undisclos new product launch
acknowledg sale carri greater risk unreal given
launch new gener launch per year past four year
base iqvia data believ estim unreason
overal bucket yield new product launch revenu north america
manag guid na repres global total like rang
believ track meet estim
figur new product revenu contribut appear line manag estim
gx advair appear achiev even
doesnt pick lot share remaind year
gener advair saw rapid uptak first week launch sinc
mylan experi initi gener copaxon uptak overhang throughout
share month market gener advair potenti see
faster uptak retail vs specialti pharmaci product abl captur
advair disku market three week share larg remain stagnant
last four
figur gener advair disku penetr steadi low rang
medacorp kol indic net price brand like par/less expens
gener
spoke two medacorp kol understand util payer level gener
advair explor reason gener penetr quickli plateau one kol
indic list price discount gener translat roughli net
price discount vs brand howev kol hypothes gsk may seen fast
initi uptak gener subsequ decid step rebat order stop
bleed plan administr note inclus advair brand-before-gener
program brand cover pbm gener program
patient abl pay cheaper co-pay addit rebat gsk pbm
would pass member plan essenc kol indic despit
list price discount net cost gener current better brand
choos cover gener vs brand involv trade-off disrupt
patient current experi vs time realiz cost save
go brand-befor gener option plan would disrupt patient experi
forc exist patient brand switch gener util mylan inhub devic
vs advair disku devic kol indic retail pharmacist like take
time counsel patient use differ inhub devic unfamiliar
gener take time work
contrast plan cover brand would realiz price benefit gener
immedi patient would want stick brand would need pay
would involv higher co-pay daw dispense-as-written differenti equal net
price differ brand gener up-front payment would contrast
back-end rebat pay-out brand-before-gener program would quarter
kol indic continu evalu differ option see
provid best price differenti understand gener lower
price greater likelihood plan move gener cover brand
rational greater price discount gener mean immedi cost save
kol believ make harder plan go rebat option
kol believ current level gener util unlik last
gener need lower price level drive chang
interestingli kol strongli emphas get market penetr
origin expect within next month may decid lower price
remain seen low low enough kol estim could addit
list price current gener net price
kol also indic intrigu dichotomi brand-before-gener program vs mandatori
gener program broadli place design drive gener util
creat confus member pharmaci level process claim accur
incorpor aggress price approach believ
current market share like remain
latest advair estim incorpor follow element
latest iqvia script trend put gener share total
fluticasone/salmeterol market month march
 reduct price gener subsequ increas
market share quarter
 price reduct list price current net price start
allow roughli doubl market share
forecast wixela sale prior estim
incorpor higher sale faster initi uptak off-set lower sale
due assum addit reduct price
revis number slightli consensu remain seen
market exactli evolv
revis estim vs consensu howev unclear mani
street estim reflect recent stagnat gener market penetr consensu
model assum play rest acknowledg multipl
unknown forecast progress particularli actual decid cut
price gsk would will match estim assum gradual ramp share gain
assum price cut mid-year base saw initi uptak
februari could instead step-wis increas market share addit
assum list price reduct juli equival exist gener net price
smaller list price reduct could suffici drive market share two aspect
combin would drive addit revenu believ take
conserv outlook revenu forecast
believ gener copaxon experi certainli shape manag perspect
strategi advair list price cut gener copaxon like
immedi effect hope see mylan uptak slowli acceler
earli potenti better line sight addit gener competit advair
market believ like seek maxim market share prior addit
entrant come
could gsk respond price cut provid cost reduct certainli
possibl medacorp kol spoke believ unlik point plan
recept gener immedi up-front cost save
bring magnitud price differenti may exceed gsk appetit increas co-pay
assist amount uncov patient gsk may feel worth push
asthma/copd product breo
note quarter add fy fy estim like includ quarterli estim
even pick share remaind believ
still achiev target
assum addit price discount remaind keep mylan
share low rang still yield sale estim
believ current assumpt price discount acceler market share
aggress see achiev sale amount wixela
ii earli data trend support fulphila
initi biosimilar neulasta trend via symphoni posit manufactur
far symphoni volum data appear correl well manag commentari
market share note call novemb reach pre-
fill syring market indic overal pegfilgrastim market earn
call mp note quarter retain share pegfilgrastim market
far symphoni data first two month indic
share coheru udenyca get estim market share march assum
modest growth market share biosimilar
figur pack syring volum trend pegfilgrastim market
coheru pre-announc exceed consensu expect
believ could suggest upsid current fulphila estim
last friday coheru releas preliminari sale udenyca
significantli higher cover analyst estim impli sale
total coheru indic januari shipment syring first
day launch even assum amount carry-through inventori flow
still impli demand-driven sale amount least quarter although
get march data anoth two week surfac pre-announc sale suggest
biosimilar penetr march could current assumpt
maintain market share estim fulphila remov risk adjust
sale estim overal consensu
despit pre-announc sale total coheru make minim chang market
share assumpt neulasta biosimilar look march symphoni data along
addit commentari coheru earn call
make chang pegfilgrastim model howev origin risk-adjust
number reflect potenti suppli constraint fulphila continu uptak
manag commentari continu suggest suppli line initi launch strategi
therefor choos remov risk-adjust rais sale
consensu number appear impli biosimilar captur pegfilgrastim market
symphoni data indic biosimilar captur market februari
month alon see reason uptak would progress continu throughout
year therefor see estim biosimilar market share
note quarter add fy fy estim like includ quarterli estim
iqvia data suggest contribut
launch product could
manag includ revenu contribut launch product
estim criteria sale within first month launch
gener count exampl product launch juli
revenu gener januari june count toward new product
question aris attempt estim new product contribut
estim initi launch trajectori product product
includ
estim initi launch trajectori look iqvia data
product past year initi sale data
take simpl averag sale total construct regress curv
launch uptak month launch independ variabl
identifi product newli launch specif
brake model includ base busi gener sale
estim first launch trajectori product
use iqvia sale data histor month product alreadi
market
 estim remain month month launch trajectori use
regress curv scale up/down estim base sale
magnitud differ specif product far vs regress
use captur rate translat iqvia sale actual sale impli
model base estim iqvia sale new product revenu
contribut believ compani actual sale
contribut us
impli sale contribut product specif broken model
includ estim us base busi gener product
figur list product estim contribut
figur contribut estim new product launch
iv eros trend oral solid busi appear
moder lower estim y/i headwind impact
sale headwind oral solid busi morgantown come better
previou expect
manag indic februari continu execut restructur remedi
activ morgantown facil signific new product revenu forecast
facil top gross margin product current manufactur
importantli manag note believ neg financi impact
busi larg behind
previous publish analysi model impact
morgantown facil base iqvia data oral solid busi previou analysi
includ iqvia data novemb assum slight worsen impact
earli yield estim y/i impact morgantown
three month addit data see eros level come better prior
expect continu adopt framework model impact
improv trend start year mean estim y/i impact morgantown
reduc
figur svb leerink estim eros trend mylan us oral solid busi
figur estim morgantown yield y/i declin
brand
type event
event trial detail
up/down
expect
outcom strateg review
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
advair assum get approv
letairi approv end march
ulor settlement june tent approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
januvia franchis assum compound patent tent approv
treanda assum launch end bendeka ode dec
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
